Treatment With AZD4547 for Recurrent Malignant Glioma Expressing FGFR-TACC Gene Fusion"
Status:
Completed
Trial end date:
2018-10-01
Target enrollment:
Participant gender:
Summary
The investigators will look for the presence of the fusion gene in all patients operated on
for glioma. This search will be limited to all gliomas that show no IDH1 mutation, the latter
being sought in both routine and anomalies never co-existing.
The hypothesis is that the rate of progression-free survival in grade IV gliomas and III
without IDH1 mutation, with the usual chemotherapy, only 15% at 6 months (ie, 85% of patients
relapse before 6 months of treatment), must be with this new treatment 35% (primary
endpoint).
The main objective is the evaluation of disease-free survival at 6 months.